The In re NextGen Healthcare, Inc. Shareholder Litigation is a class action lawsuit filed in Delaware Chancery Court by shareholders of NextGen Healthcare, Inc., a provider of electronic health record and practice management software. The suit challenges the fairness of the company's 2021 acquisition by private equity firm Thoma Bravo, L.P. and its affiliates for $1.7 billion, or $17.70 per share. Filed shortly after the February 9, 2021 merger announcement, the litigation alleged that the board of directors breached their fiduciary duties by failing to maximize shareholder value, conducting an inadequate sales process, and agreeing to an undervalued price amid conflicts of interest. The case highlighted typical M&A litigation concerns in Delaware, focusing on Revlon duties for sales of control. It was consolidated and resulted in a settlement providing supplemental proxy disclosures to address disclosure deficiencies, without monetary compensation, which the court approved.